The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Vaccine manufacturing is lumpy, supply not as good as hoped, UK says

Mon, 18th Jan 2021 08:16

* UK says AstraZeneca slower than hoped

* UK says Pfizer changes may lead to delays

* UK is vaccinating 140 people per minute on average
(Recasts headline and lead with manufacturing issues)

By Guy Faulconbridge and Kate Holton

LONDON, Jan 18 (Reuters) - Britain's vaccine rollout is
limited by a "lumpy" manufacturing process with production
changes by Pfizer and a delay by AstraZeneca
that could lead to brief supply disruption, Vaccine Deployment
Minister Nadhim Zahawi said on Monday.

The United Kingdom, which has the world's fifth worst
official COVID-19 death toll, is racing to be among the first
major countries to vaccinate its population - seen as the best
way to exit the pandemic and get the economy going again.

The United Kingdom has vaccinated 3,857,266 people with a
first dose and 449,736 with a second dose. On vaccines
administered per 100 people, the United Kingdom is fourth in the
world after Israel, the United Arab Emirates and Bahrain.

Zahawi told LBC radio that the United Kingdom was hoping for
2 million vaccines a week from AstraZeneca but that
those numbers will not be reached until mid February. Still, he
said the UK was on course to hit its rollout targets.

"It's been a bit lumpy," Zahawi said of vaccine manufacture.

Pfizer will temporarily reduce its deliveries to Europe of
its vaccine against COVID-19 while it upgrades its production
capacity.

"There's bound to be delays. Any new manufacturing process
has challenges at the outset, it is lumpy, it begins to
stabilise and get better and better week in, week out," Zahawi
told the BBC.

"The Pfizer BioNTech vaccine is a messenger RNA chemical,
difficult chemical to manufacture, very very challenging but
they're doing really well, they want to do more which is why
they're reconfiguring to add volume to the whole world," Zahawi
said.

"That could delay supply but I'm confident we can meet our
target."

VACCINE HOPES

Mass COVID-19 vaccines are seen as the best way to exit the
pandemic which has killed more than 2 million people, wiped out
trillions of dollars in economic output and upended normal life
for people across the world.

The United Kingdom is vaccinating 140 people per minute
against COVID-19 on average.

"It is going well, we're vaccinating on average 140 people,
that's first jab, literally a minute. That's the average so some
areas are doing better," Zahawi told Sky.

Britain is currently rolling out the vaccine to the most
vulnerable first, starting with those who are in care homes or
over 80 years of age. In areas where a majority of over 80s have
been offered a vaccine, letters are going out to the over 70s
and those who are clinically extremely vulnerable.

Zahawi said a 24-hour vaccine offering would begin to be
piloted in London by the end of the month.

Essential workers such as teachers, the police and shop
assistants could move to the top of the list for a vaccine once
all those over 50 have been offered a shot, Zahawi said.

"Teachers, police officers, shop workers, those who through
no fault of their own other than the work that they do may come
into contact with the virus in much greater volume, should be
top of the list," Zahawi told Times Radio.
(Reporting by Guy Faulconbridge and Kate Holton; editing by
Sarah Young, Paul Sandle and Philippa Fletcher)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.